Compounded Injectable Drug Recalled for Lack of Sterility Assurance
Northern VA Compounders PLLC is recalling 1,200 vials of BiMix STD 001 injectable nationwide due to lack of assurance of sterility. The compounded drug cannot be verified as sterile.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of an injectable medication due to lack of sterility assurance. No illnesses or injuries have been reported, and the hazard is theoretical. Per the rubric, this is a risk-of-harm product where injury has not yet been reported, classified as High (3).
Plain-English summary
BiMix STD 001 is a compounded injectable medication containing Papaverine HCl and Phentolamine Mesylate, manufactured by Northern VA Compounders PLLC and compounded by Akina Pharmacy in Sterling, Virginia. The recall involves 2.5 mL multiple-dose vials (Lot 10252022@3, expiration date 1/31/2023).
The FDA Class II recall was issued due to lack of assurance of sterility. The manufacturer cannot verify that the product was produced under the strict sterile conditions required for injectable medications.
The recalled product was distributed nationwide in the United States. Patients who have this medication should contact their healthcare provider or pharmacist.
The recalled product
- Product
- BiMix STD 001 (Papaverine HCl/Phentolamine Mesylate) 30mg/1mg/mL INJECTABLE, 2.5 mL Multiple-Dose vials, Rx Only, Compounded by: Akina Pharmacy, 23475 Rock Haven Way Suite 105, Sterling, VA 20166.
- Manufacturer
- Northern VA Compounders PLLC
- Category
- Drug — Compounded Injectable
- Hazard
- contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 10252022@3
- Exp 1/31/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateCorlanor ivabradine tablets recalled for presence of foreign substance
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01